PMID- 28721055
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20201001
IS  - 1176-6336 (Print)
IS  - 1178-203X (Electronic)
IS  - 1176-6336 (Linking)
VI  - 13
DP  - 2017
TI  - Chitosan oligosaccharide improves the therapeutic efficacy of sitagliptin for the 
      therapy of Chinese elderly patients with type 2 diabetes mellitus.
PG  - 739-750
LID - 10.2147/TCRM.S134039 [doi]
AB  - Sitagliptin improves glycemic control in type 2 diabetes mellitus (T2DM) patients 
      but its side effects are undesirable. Chitosan oligosaccharide (COS) is expected 
      to improve the therapeutic result as a natural product. A total of 200 elderly 
      T2DM patients were evenly assigned into four groups: sitagliptin group (SG), 
      receiving sitagliptin 100 mg/day; COS group (CG), receiving COS 100 mg/day; 
      combination therapy of sitagliptin and COS group (SCG), receiving both 
      sitagliptin and COS 100 mg/day; and placebo group (PG), receiving placebo 100 
      mg/day. After 42-week therapy, biochemical indices and clinical parameters for 
      the alterations from start points were analyzed. The related molecular mechanism 
      was tested by quantitative real-time polymerase chain reaction (qRT-PCR) and 
      Western blot at cell level. Lower risk of hypoglycemia was found in the SCG group 
      when compared with SG and other groups (P<0.05). More patients from the SCG group 
      than other groups attained hemoglobin A1c (HbA1c) reduction >2.5% (P<0.05). 
      Weight reduction of 1.2+/-0.9, 2.6+/-0.8, 4.7+/-1.3, and 0.9+/-0.6 kg was observed in the 
      patients from SG, CG, SCG, and PG groups, respectively (P<0.05). The combined 
      treatment of COS and sitagliptin presented better therapeutic results by 
      improving insulin sensitivity, lipid profile, adiponectin levels, and 
      glucagon-like peptide 1 and reducing side effects, insulin resistance, HbA1c, 
      body mass index, resistin, tumor necrosis factor (TNF)-alpha, and C-reactive protein 
      (CRP) (P<0.05). qRT-PCR and Western blot analysis also showed that COS treatment 
      reduced the levels of resistin, TNF-alpha, and CRP, and increased the level of 
      adiponectin. The combination of COS and sitagliptin provided better glycemic 
      control with fewer side effects and with more weight reduction in the elderly 
      participants with T2DM.
FAU - Zhao, Lijie
AU  - Zhao L
AD  - Department of Geriatrics.
FAU - Sun, Tingli
AU  - Sun T
AD  - Department of Nephrology, General Hospital of Daqing Oil Field, Daqing, China.
FAU - Wang, Lina
AU  - Wang L
AD  - Department of Geriatrics.
LA  - eng
PT  - Journal Article
DEP - 20170627
PL  - New Zealand
TA  - Ther Clin Risk Manag
JT  - Therapeutics and clinical risk management
JID - 101253281
PMC - PMC5499789
OTO - NOTNLM
OT  - C-reactive protein
OT  - adiponectin
OT  - chitosan oligosaccharide
OT  - glucagon-like peptide 1
OT  - insulin sensitivity
OT  - sitagliptin
OT  - type 2 diabetes mellitus
COIS- Disclosure The authors report no conflicts of interest in this work.
EDAT- 2017/07/20 06:00
MHDA- 2017/07/20 06:01
PMCR- 2017/06/27
CRDT- 2017/07/20 06:00
PHST- 2017/07/20 06:00 [entrez]
PHST- 2017/07/20 06:00 [pubmed]
PHST- 2017/07/20 06:01 [medline]
PHST- 2017/06/27 00:00 [pmc-release]
AID - tcrm-13-739 [pii]
AID - 10.2147/TCRM.S134039 [doi]
PST - epublish
SO  - Ther Clin Risk Manag. 2017 Jun 27;13:739-750. doi: 10.2147/TCRM.S134039. 
      eCollection 2017.